97. 潰瘍性大腸炎 Ulcerative colitis Clinical trials / Disease details
臨床試験数 : 2,630 / 薬物数 : 1,459 - (DrugBank : 265) / 標的遺伝子数 : 144 - 標的パスウェイ数 : 202
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT03724175 (ClinicalTrials.gov) | August 26, 2019 | 12/10/2018 | The Role of Secondary Bile Acids in Intestinal Inflammation | The Role of Secondary Bile Acids in Intestinal Inflammation | Ulcerative Colitis;Pouchitis | Drug: ursodiol (ursodeoxycholic acid, UDCA) | Stanford University | NULL | Recruiting | 18 Years | 70 Years | All | 15 | Phase 2/Phase 3 | United States |
2 | ChiCTR2000038316 | 2018-08-01 | 2020-09-17 | Effect of ursodeoxycholic acid on ulcerative colitis and serumal IL-23, IL-17 and intestinal flora levels | Effect of ursodeoxycholic acid on ulcerative colitis and serumal IL-23, IL-17 and intestinal flora levels | Ulcerative colitis | control group:Mesalazine alone;trial group:Mesalazine and ursodeoxycholic acid soft capsule;Patients with mild bile reflux gastritis: ursodeoxycholic acid soft capsule;Healthy control group:Nil; | The 900th Hospital of PLA | NULL | Completed | 18 | 75 | Both | control group:20;trial group:20;Patients with mild bile reflux gastritis:20;Healthy control group:20; | Phase 4 | China |
3 | EUCTR2009-010921-38-NL (EUCTR) | 08/09/2009 | 02/03/2009 | Chemopreventive effects of 5-ASA and UDCA in Ulcerative Colitis:A Double-blind, Randomized Placebo-controlled Pilot Study - CRC chemoprevention in UC | Chemopreventive effects of 5-ASA and UDCA in Ulcerative Colitis:A Double-blind, Randomized Placebo-controlled Pilot Study - CRC chemoprevention in UC | Ulcerative Colitis and the risk of developing colorectal cancer. MedDRA version: 13.1;Level: PT;Classification code 10021972;Term: Inflammatory bowel disease;System Organ Class: 10017947 - Gastrointestinal disorders | Trade Name: Salofalk INN or Proposed INN: mesalazine Trade Name: Ursofalk INN or Proposed INN: ursodeoxycholic acid | UMC Utrecht | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | Netherlands |